Nanomedicine-Driven Modulation of the Gut–Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer’s and Parkinson’s Disease
Open Access
- 19 September 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9178
Abstract
Chronic inflammation plays a crucial role in the pathogenesis and progression of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), where sustained neuroinflammatory responses contribute to neuronal damage and functional decline. Recent advances in nanomedicine offer novel therapeutic strategies aimed at modulating inflammation, with a focus on targeting the gut–brain axis, a key mediator in the interplay between systemic inflammation and neurodegeneration. Artificial intelligence (AI) has emerged as a transformative tool in this context, facilitating the integration of large, complex datasets to better understand the intricate relationship between gut microbiota dysbiosis, chronic neuroinflammation, the exposome (cumulative impact of lifelong environmental exposures), and disease manifestation. AI-driven approaches and integrating exposome data with AI enable deeper insights into exposure–microbiome–inflammation interactions, enhance our understanding of the inflammatory pathways involved, support the development of predictive models for disease progression, and optimize the delivery of nanomedicine-based therapeutics. Additionally, AI applications in neuroimaging and personalized therapy planning have shown promise in addressing both motor and non-motor symptoms. This review provides a comprehensive synthesis of current knowledge, highlighting the convergence of AI, nanomedicine, and chronic inflammation in neurodegenerative disease care.Keywords
This publication has 306 references indexed in Scilit:
- Artificial Intelligence/Machine Learning: The New Frontier of Clinical Pharmacology and Precision MedicineClinical Pharmacology & Therapeutics, 2024
- The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)Alzheimer's & Dementia, 2023
- The long‐term effectiveness and cost‐effectiveness of public health interventions; how can we model behavior? A reviewHealth Economics, 2023
- Three‐dimensional bioprinting of stem cell‐derived central nervous system cells enables astrocyte growth, vasculogenesis, and enhances neural differentiation/functionBiotechnology and Bioengineering, 2023
- Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)Alzheimer's & Dementia, 2021
- Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood–Brain BarrierAdvanced Materials, 2020
- 3D Bioprinting of Neural TissuesAdvanced Healthcare Materials, 2020
- A Machine Learning‐Assisted Nanoparticle‐Printed Biochip for Real‐Time Single Cancer Cell AnalysisAdvanced Biosystems, 2020
- The Parkinson Pandemic—A Call to ActionJAMA Neurology, 2018
- Early detection of Alzheimer's disease using MRI hippocampal textureHuman Brain Mapping, 2015